Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1651679 | 1.00 | POLB (0.39) | POLBL3MBTL1TP53PSEN1PSEN2 | |
| SCHEMBL8602693 | 0.90 | S1PR1 (0.43) | TP53MAPTGRM5KMT2A | |
| SCHEMBL4780628 | 0.90 | S1PR1 (0.43) | TP53MAPTGRM5KMT2A | |
| SCHEMBL7692006 | 0.87 | S1PR1 (0.50) | TP53MAPTKMT2A | |
| SCHEMBL14413594 | 0.85 | KMT2A (0.50) | L3MBTL1MAPTALDH1A1KMT2A | |
| SCHEMBL4732559 | 0.84 | POLB (0.42) | POLBL3MBTL1MAPTKMT2A | |
| SCHEMBL8365982 | 0.84 | AKR1C3 (0.46) | POLBL3MBTL1TP53 | |
| SCHEMBL22371739 | 0.84 | NPC1 (0.40) | POLBL3MBTL1TP53PSEN1PSEN2 | |
| SCHEMBL20819833 | 0.84 | NPC1 (0.40) | POLBL3MBTL1TP53PSEN1PSEN2 | |
| SCHEMBL14645821 | 0.84 | NPC1 (0.40) | POLBL3MBTL1TP53PSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9102628-B2 | Derivatives of pyrazole 3,5-carboxylates, their preparation and their application in therapeutics | SANOFI (FR) | 2015-08-11 | — | — | US | disclosed |
| US-20100160377-A1 | DERIVATIVES OF PYRAZOLE 3,5-CARBOXYLATES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160377-A1 | DERIVATIVES OF PYRAZOLE 3,5-CARBOXYLATES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | CYP3A5, ADH5, AVPR2 | POLB 2563/4885L3MBTL1 3053/4885TP53 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.